| Jon Hart Scarpino, MD | |
|
932 Ward Ave, #460, Honolulu, HI 96814-2131 | |
| (808) 521-6564 | |
| Not Available |
| Full Name | Jon Hart Scarpino |
|---|---|
| Gender | Male |
| Speciality | Legal Medicine |
| Location | 932 Ward Ave, Honolulu, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780725481 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Jon Hart Scarpino, MD 932 Ward Ave, #460, Honolulu, HI 96814-2131 Ph: (808) 521-6564 | Jon Hart Scarpino, MD 932 Ward Ave, #460, Honolulu, HI 96814-2131 Ph: (808) 521-6564 |
News Archive
Their method uses "Cellular Analysis and Notification of Antigen Risks and Yields" (CANARY) cells, which are immune-system cells engineered to contain a fluorescent protein naturally found in jellyfish. CANARY cells have the immune system's ability to detect specific disease-causing agents, lighting up when they recognize a pathogen.
Researchers in the United States and Japan have conducted a study suggesting that a commonly occurring genetic variant influences susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).
Few women go through life having never suffered from the uncomfortable symptoms of a yeast infection. In fact, nearly 3 in 4 (72 percent) women will experience their first yeast infection before age 25. Furthermore, the incidence of yeast infections is highest among young women ages 18-24, who are new to the category and uncertain about symptoms and available treatment options.
To induce an illusory perception of the material properties of the hand, a group of neuroscientists from Bielefeld University, the Max-Planck Institute for Biological Cybernetics (Germany), and the University of Milano-Bicocca (Italy) asked volunteers to sit with their hands lying on a table in front of them.
Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.
› Verified 1 days ago